NCT05613205 - Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

December 6, 2023

Study Completion Date

April 2, 2024

Conditions

Typhoid Fever

Interventions

BIOLOGICAL

TYP04A Low Dose without Alum investigational vaccine

2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

BIOLOGICAL

TYP04B Full Dose without Alum investigational vaccine

2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

BIOLOGICAL

TYP03A Low Dose with Alum investigational vaccine

2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

BIOLOGICAL

TYP03B Full Dose with Alum investigational vaccine

2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

BIOLOGICAL

Sanofi Pasteur's Typhoid Vi polysaccharide vaccine

1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.

BIOLOGICAL

GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine

1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.

Trial Locations (1)

2610

GSK Investigational Site, Edegem